

Executive Officer Notice: Funding of Emerade™ (Epinephrine Auto-Injector) through the Allergen Program

October 21, 2020

The Executive Officer (EO) of the Ontario Public Drug Programs (OPDP) has approved funding of Emerade™ 0.3 mg/0.3 mL and 0.5 mg/0.5 mL epinephrine auto-injectors through the Allergen program. The Allergen program provides coverage for certain allergen products and extracts for individuals eligible under the Ontario Drug Benefit (ODB) program.

ODB-eligible individuals will not require a Special Authorization (Allergen) (SAA) form to receive an epinephrine auto-injector (e.g. Allerject®, Emerade™, EpiPen® or EpiPen Jr®) under the Allergen program. However, a valid prescription directing the dispensing of the epinephrine auto-injector will be required for funding under the program. Note that the different brands of epinephrine auto-injectors eligible for coverage under the Allergen program are not designated as interchangeable with one another.

Effective October 21, 2020, the following Emerade™ products are funded through the Allergen program:

DIN	Brand Name	Generic Name	Strength	MFR	Unit Price/ Amount MOH Pays
02458446	Emerade™	Epinephrine (epinephrine bitartrate)	0.3 mg/0.3 mL	Bausch Health, Canada Inc.	\$81.0000
02458454	Emerade™	Epinephrine (epinephrine bitartrate)	0.5 mg/0.5 mL	Bausch Health, Canada Inc.	\$81.0000

Background on the Allergen program

The Allergen program provides first dollar coverage for ODB program recipients for certain drug products used to treat allergies and allergic reactions.

Allergen extract products funded through the Allergen program may be provided by an authorized allergen extract supplier or an accredited retail pharmacy.

Additional Information:

For pharmacies:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282